Stress-protective properties of lithium nicotinate, a new nicotinic acid derivative

Kresyun, V. I.

doi:10.1007/bf00800833

Cited by 1 publication

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors hypothesize that this is due to synergistic anti-inflammatory actions of lithium and acetylsalicylic acid by increasing the brain concentrations of 17-OH-DHA, an anti-inflammatory brain DHA metabolite. This hypothesis is supported by previous studies that demonstrated neuroinflammation in BD, that aspirin increases 17-OH-DHA, and that lithium reduces neuroinflammation. − Lithium nicotinate has been used in Russia for the treatment of alcoholism − and stress. , This lithium salt is distinguished by low toxicity and good tolerance . Collectively, these findings suggest that lithium salicylate and lithium nicotinate might be advantageous to current FDA-approved lithium salts from efficacy and toxicity standpoints, respectively.…”

Section: Discussionsupporting

confidence: 58%

“…54−56 Lithium nicotinate has been used in Russia for the treatment of alcoholism 57−59 and stress. 60,61 This lithium salt is distinguished by low toxicity and good tolerance. 58 36,38 Although racetams generally possess good toxicity profiles and might prove to act synergistically with lithium, bromide salts have been known to cause serious side effects that were coined bromism.…”

Section: ■ Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Improving Lithium Therapeutics by Crystal Engineering of Novel Ionic Cocrystals

et al. 2013

View full text Add to dashboard Cite

Current United States Food and Drug Administration (FDA)-approved lithium salts are plagued with a narrow therapeutic window. Recent attempts to find alternative drugs have identified new chemical entities, but lithium’s polypharmacological mechanisms for treating neuropsychiatric disorders are highly debated and are not yet matched. Thus, re-engineering current lithium solid forms in order to optimize performance represents a low cost and low risk approach to the desired therapeutic outcome. In this contribution, we employed a crystal engineering strategy to synthesize the first ionic cocrystals (ICCs) of lithium salts with organic anions. We are unaware of any previous studies that have assessed the biological efficacy of any ICCs, and encouragingly we found that the new speciation did not negatively affect established bioactivities of lithium. We also observed that lithium ICCs exhibit modulated pharmacokinetics compared to lithium carbonate. Indeed, the studies detailed herein represent an important advancement in a crystal engineering approach to a new generation of lithium therapeutics.

show abstract